title: Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus.
abstract: Hyperuricaemia is associated with an increased risk of gout, kidney stones and cardiovascular disease. The present post hoc analysis of pooled data from four placebo-controlled phase III studies assessed the effect of canagliflozin, a sodium-glucose co-transporter 2 inhibitor, on serum uric acid levels in patients with type 2 diabetes mellitus (T2DM) and in a subset of patients with hyperuricaemia [defined as baseline serum uric acid ≥475 µmol/l (∼8 mg/dl)]. At week 26, canagliflozin 100 and 300 mg were associated with a ∼13% reduction in serum uric acid compared with placebo. In the subset of patients with hyperuricaemia, placebo-subtracted percent reductions in serum uric acid were similar to those in the overall cohort. More patients in the hyperuricaemic group achieved a serum uric acid level of <360 µmol/l (∼6 mg/dl) with both canagliflozin 100 mg (23.5%) and 300 mg (32.4%) compared with placebo (3.1%). Incidences of gout and kidney stones were low and similar across groups. In conclusion, canagliflozin treatment decreased serum uric acid in patients with T2DM, including those with baseline hyperuricaemia.
authors.affiliation: Janssen Scientific Affairs LLC, Raritan, NJ, USA.
authors.forename: M J
authors.initials: MJ
authors.lastname: Davies
authors.forename: A
authors.initials: A
authors.lastname: Trujillo
authors.forename: U
authors.initials: U
authors.lastname: Vijapurkar
authors.forename: C V
authors.initials: CV
authors.lastname: Damaraju
authors.forename: G
authors.initials: G
authors.lastname: Meininger
mesh_terms: D000328:Adult; D000368:Aged; D000068896:Canagliflozin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation; D004359:Drug Therapy, Combination / Q000009:adverse effects; D005260:Female; D006073:Gout / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D033461:Hyperuricemia / Q000150:complications / Q000503:physiopathology / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015994:Incidence; D007669:Kidney Calculi / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D012306:Risk; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D014527:Uric Acid / Q000097:blood*
chemical_list: D007004:Hypoglycemic Agents; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D000068896:Canagliflozin; D014527:Uric Acid
keywords: SGLT2 inhibitor; canagliflozin; diabetes complications; drug mechanism; type 2 diabetes